lifitegrast

An LFA-1 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1) antagonist that is used in the treatment of DRY EYE SYNDROMES.

Also Known As:

(2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid; L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-; SAR 1118; SAR-1118; SHP-606; SHP606; Xiidra; lifitegrast ophthalmic solution

Networked: 67 relevant articles (10 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nichols, Kelly K: 6 articles (01/2022 - 06/2016)
2.	Raychaudhuri, Aparna: 6 articles (07/2019 - 12/2015)
3.	Shojaei, Amir: 6 articles (07/2019 - 01/2016)
4.	Semba, Charles P: 6 articles (06/2016 - 02/2011)
5.	Donnenfeld, Eric D: 5 articles (01/2022 - 06/2016)
6.	Karpecki, Paul: 4 articles (08/2022 - 12/2015)
7.	Karpecki, Paul M: 4 articles (07/2019 - 06/2016)
8.	Gadek, Thomas R: 4 articles (01/2016 - 02/2011)
9.	O'Neill, Charles A: 4 articles (05/2013 - 10/2010)
10.	Hovanesian, John A: 3 articles (01/2022 - 07/2019)

Related Diseases

1.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2022 - "Our results demonstrated that one of these analogues of Lifitegrast (compound 1b) showed good LFA-1/ICAM-1 antagonist activity in in vitro assay; meanwhile, it also significantly reduced ocular surface epithelial cells damage, increased goblet cell density in dry eye mouse and highly improved the symptoms of dry eye mouse. " 09/01/2016 - "Clinical trials in over 2,500 subjects with dry eye disease have shown that 5.0% lifitegrast given by ocular instillation causes a significant reduction in objective and subjective signs and symptoms of the disease. " 01/01/2019 - "Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. " 01/01/2019 - "Lifitegrast has a novel mechanism of action and is safe and effective for the treatment of dry eye disease. " 11/01/2021 - "Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials."
2.	Dysgeusia (Parageusia) 08/26/2022 - "Lifitegrast improves DED, although dysgeusia, installation site pain, and irritation may be a concern for some. " 07/01/2019 - "Ocular treatment-emergent adverse events occurring in >5% in either group were instillation site irritation (lifitegrast, 15.2%; placebo, 2.8%), instillation site reaction (lifitegrast, 12.3%; placebo, 2.3%), and instillation site pain (lifitegrast, 9.8%; placebo, 2.1%); the most common (> 5%) nonocular treatment-emergent adverse event was dysgeusia (lifitegrast, 14.5%; placebo, 0.3%). " 01/01/2021 - "The improved performance of reproxalap with regard to the most commonly reported side effects of lifitegrast (ie, ocular discomfort, blurry vision, and dysgeusia) may result in greater patient adherence and lower discontinuation rates." 01/01/2021 - "There were lower rates of negative responses for both reproxalap formulations compared to lifitegrast across ocular discomfort, blurry vision, and dysgeusia assessments, and the durations of negative responses were shorter with reproxalap than with lifitegrast. " 01/01/2021 - "Both reproxalap formulations scored better in ocular discomfort score (ODS), blurry vision, and dysgeusia assessments than lifitegrast at each timepoint and cumulatively over all time points after instillation. "
3.	Cataract (Cataracts) 01/01/2020 - "Lifitegrast 5% significantly improved preoperative corneal surface measurement accuracy in patients with confirmed dry eye who were scheduled for cataract surgery." 01/01/2020 - "To determine the effect of lifitegrast ophthalmic solution 5% on improving the tear film, biometry/keratometry, and refractive accuracy for dry eye patients scheduled for cataract surgery. " 01/01/2020 - "The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery."
4.	Inflammation (Inflammations) 10/01/2017 - "Of note, in 2 phase 3 trials, symptom improvements were observed as early as 2 weeks, which may be explained by lifitegrast's unique mechanism of action of blocking a specific signaling pathway in inflammation. " 04/01/2020 - "We compared efficacy and safety of treatment to reduce inflammation (lifitegrast) versus obstruction [thermal pulsation procedure (TPP)] in patients with inflammatory MGD over 42 days. " 01/01/2019 - "Lifitegrast is a novel drug designed to inhibit DED-associated ocular inflammation. " 01/01/2017 - "Notably, inhibition of LFA-1/ICAM-1 binding with lifitegrast offers a novel approach to reducing ocular surface inflammation in this condition." 08/01/2022 - "Lifitegrast is a 5% ophthalmic solution of a lymphocyte function-associated antigen 1 antagonist that is believed to target T cell activation and recruitment to inhibit ocular inflammation. "
5.	Pain (Aches) 08/26/2022 - "Lifitegrast improves DED, although dysgeusia, installation site pain, and irritation may be a concern for some. " 07/01/2019 - "Ocular treatment-emergent adverse events occurring in >5% in either group were instillation site irritation (lifitegrast, 15.2%; placebo, 2.8%), instillation site reaction (lifitegrast, 12.3%; placebo, 2.3%), and instillation site pain (lifitegrast, 9.8%; placebo, 2.1%); the most common (> 5%) nonocular treatment-emergent adverse event was dysgeusia (lifitegrast, 14.5%; placebo, 0.3%). " 01/01/2017 - "Other secondary efficacy end points included additional VAS items (burning/stinging, itching, foreign body sensation, eye discomfort, photophobia, pain), ocular discomfort score (ODS), and safety/tolerability of lifitegrast versus placebo. "

Related Drugs and Biologics

1.	Varenicline (Chantix)
2.	Ophthalmic Solutions (Eye Drops)
3.	Nasal Sprays
4.	Solutions
5.	Indicators and Reagents (Reagents)
6.	reproxalap
7.	Cyclosporine (Ciclosporin)
8.	lifitegrast
9.	Lymphocyte Function-Associated Antigen-1 (LFA-1)
10.	Integrins

Related Therapies and Procedures

1.	Therapeutics
2.	Contact Lenses
3.	Immunomodulation
4.	Transplantation
5.	Surgical Amputation (Amputations)